Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Arcturus Therapeutics Holdings (ARCT) Equity Average (2018 - 2025)

Arcturus Therapeutics Holdings (ARCT) has disclosed Equity Average for 8 consecutive years, with $219.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Equity Average fell 12.79% year-over-year to $219.3 million, compared with a TTM value of $219.3 million through Dec 2025, down 12.79%, and an annual FY2025 reading of $227.5 million, down 12.42% over the prior year.
  • Equity Average was $219.3 million for Q4 2025 at Arcturus Therapeutics Holdings, down from $227.8 million in the prior quarter.
  • Across five years, Equity Average topped out at $374.6 million in Q1 2021 and bottomed at $158.2 million in Q3 2022.
  • Average Equity Average over 5 years is $255.5 million, with a median of $255.8 million recorded in 2024.
  • The sharpest move saw Equity Average soared 1651.44% in 2021, then plummeted 46.0% in 2022.
  • Year by year, Equity Average stood at $243.7 million in 2021, then dropped by 14.64% to $208.0 million in 2022, then soared by 34.28% to $279.3 million in 2023, then fell by 9.98% to $251.4 million in 2024, then fell by 12.79% to $219.3 million in 2025.
  • Business Quant data shows Equity Average for ARCT at $219.3 million in Q4 2025, $227.8 million in Q3 2025, and $232.4 million in Q2 2025.